Endonovo Therapeutics (ENDV) Cost of Revenue (2018 - 2023)
Endonovo Therapeutics has reported Cost of Revenue over the past 8 years, most recently at $827.0 for Q3 2023.
- Quarterly results put Cost of Revenue at $827.0 for Q3 2023, down 79.46% from a year ago — trailing twelve months through Sep 2023 was $9689.0 (down 30.72% YoY), and the annual figure for FY2022 was $9990.0, down 33.33%.
- Cost of Revenue for Q3 2023 was $827.0 at Endonovo Therapeutics, down from $3996.0 in the prior quarter.
- Over the last five years, Cost of Revenue for ENDV hit a ceiling of $47176.0 in Q4 2019 and a floor of $383.0 in Q2 2022.
- Median Cost of Revenue over the past 5 years was $4446.5 (2022), compared with a mean of $10475.1.
- Biggest five-year swings in Cost of Revenue: soared 5276.91% in 2019 and later plummeted 95.58% in 2021.
- Endonovo Therapeutics' Cost of Revenue stood at $47176.0 in 2019, then decreased by 0.27% to $47049.0 in 2020, then plummeted by 81.17% to $8861.0 in 2021, then tumbled by 45.09% to $4866.0 in 2022, then crashed by 83.0% to $827.0 in 2023.
- The last three reported values for Cost of Revenue were $827.0 (Q3 2023), $3996.0 (Q1 2023), and $4866.0 (Q4 2022) per Business Quant data.